ATE260926T1 - Antivirale prodrugs - Google Patents

Antivirale prodrugs

Info

Publication number
ATE260926T1
ATE260926T1 AT95940014T AT95940014T ATE260926T1 AT E260926 T1 ATE260926 T1 AT E260926T1 AT 95940014 T AT95940014 T AT 95940014T AT 95940014 T AT95940014 T AT 95940014T AT E260926 T1 ATE260926 T1 AT E260926T1
Authority
AT
Austria
Prior art keywords
prodrugs
antiviral prodrugs
antiviral
phosphonoacids
analogs
Prior art date
Application number
AT95940014T
Other languages
English (en)
Inventor
Karl Y Hostetler
Ganesh D Kini Ph D
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE260926T1 publication Critical patent/ATE260926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
    • C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95940014T 1994-11-15 1995-11-15 Antivirale prodrugs ATE260926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/340,161 US5696277A (en) 1994-11-15 1994-11-15 Antiviral prodrugs
PCT/US1995/014940 WO1996015132A1 (en) 1994-11-15 1995-11-15 Improved antiviral prodrugs

Publications (1)

Publication Number Publication Date
ATE260926T1 true ATE260926T1 (de) 2004-03-15

Family

ID=23332146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940014T ATE260926T1 (de) 1994-11-15 1995-11-15 Antivirale prodrugs

Country Status (11)

Country Link
US (2) US5696277A (de)
EP (1) EP0792275B1 (de)
JP (1) JPH10508858A (de)
AT (1) ATE260926T1 (de)
AU (1) AU700651B2 (de)
CA (1) CA2205136C (de)
DE (1) DE69532642T2 (de)
DK (1) DK0792275T3 (de)
ES (1) ES2217287T3 (de)
PT (1) PT792275E (de)
WO (1) WO1996015132A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5696277A (en) * 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
TW343975B (en) * 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
SE9603726D0 (sv) * 1996-10-11 1996-10-11 Astra Ab Novel compounds
SE9604582D0 (sv) * 1996-12-13 1996-12-13 Astra Ab Novel compounds
US6686462B2 (en) 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
EP1058686B1 (de) 1998-02-25 2006-11-02 Emory University 2'-fluoronukleoside
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
US6444837B1 (en) * 1998-07-13 2002-09-03 University Of Southern California Synthesis and antiviral activity of a series of pyrophosphate analogs
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CN100387237C (zh) 1998-08-10 2008-05-14 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2'-脱氧-核苷
ES2314157T3 (es) 1998-11-02 2009-03-16 Gilead Sciences, Inc. Terapia de combinacion para tratar el virus de la hepatitis b.
KR20020073494A (ko) * 1999-12-29 2002-09-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 약물내성 인체 면역결핍 바이러스 감염의 치료
RU2265439C2 (ru) * 2000-01-04 2005-12-10 Де Риджентс Ов Де Юниверсити Ов Калифорния Лечение инфекции вируса иммунодефицита человека с лекарственной устойчивостью
CA2405502A1 (en) 2000-03-29 2001-10-04 Georgetown University Method of treating hepatitis delta viral infection
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
JP2004533406A (ja) 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
WO2002087500A2 (en) * 2001-04-27 2002-11-07 Newbiotics, Inc. Viral enzyme activated prototoxophores and use of same to treat viral infections
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
AU2003278816A1 (en) 2002-09-13 2004-04-30 Idenix (Cayman) Limited ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
AU2003278904A1 (en) * 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US20070207973A1 (en) * 2002-09-24 2007-09-06 Koronis Pharmaceuticals, Incorporated 1,3,5-Triazines for Treatment of Viral Diseases
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
RU2005123395A (ru) * 2002-12-23 2006-01-27 Айденикс (Кайман) Лимитед (Ky) Способ получения 3-нуклеозидных пролекарств
BRPI0419345B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc uso do (2’r)-2’-desoxi-2’-flúor-2’-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
DK1658302T3 (da) 2003-07-25 2010-11-22 Idenix Pharmaceuticals Inc Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
WO2005045310A2 (en) * 2003-10-27 2005-05-19 Wimberly Randal L Dual reflector system
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
MX2007003085A (es) 2004-09-14 2007-08-02 Pharmasset Inc Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
JP2008538354A (ja) 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
NZ567272A (en) 2005-09-26 2012-02-24 Pharmasset Inc Modified 4'-nucleosides as antiviral agents
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
US7950880B2 (en) * 2006-10-18 2011-05-31 Kennametal Inc. Spiral flute tap
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101977610B (zh) 2008-01-25 2012-05-16 奇默里克斯公司 治疗病毒感染的方法
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
SMT201800538T1 (it) 2013-03-15 2019-01-11 Univ California Diesteri di fosfonato nucleosidico aciclico
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
HRP20220651T1 (hr) 2014-09-15 2022-08-19 The Regents Of The University Of California Nukleotidni analozi
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
WO2018023054A1 (en) * 2016-07-28 2018-02-01 Kansas State University Research Foundation Protease transition state inhibitor prodrugs
JP7465416B2 (ja) * 2018-06-26 2024-04-11 ティーエスアールエル インコーポレイテッド 代謝安定性プロドラッグ
CA3152013A1 (en) 2019-08-22 2021-02-25 Emory University Nucleoside prodrugs and uses related thereto
JP2025526212A (ja) 2022-07-21 2025-08-13 アンティバ バイオサイエンシズ インコーポレイテッド Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7607496L (sv) * 1976-07-01 1978-01-02 Astra Laekemedel Ab Sett for bekempning av virusinfektioner
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US5072032A (en) * 1989-06-21 1991-12-10 Mckenna Charles E Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
EP0673256A4 (de) * 1992-12-09 1997-01-29 Indiana University Foundation Unterdrückung von myeloidzellen.
US5696277A (en) * 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs

Also Published As

Publication number Publication date
US6002029A (en) 1999-12-14
PT792275E (pt) 2004-09-30
DE69532642T2 (de) 2005-06-30
US5696277A (en) 1997-12-09
EP0792275A1 (de) 1997-09-03
DE69532642D1 (de) 2004-04-08
JPH10508858A (ja) 1998-09-02
AU700651B2 (en) 1999-01-14
CA2205136C (en) 2008-01-22
AU4163596A (en) 1996-06-06
WO1996015132A1 (en) 1996-05-23
EP0792275A4 (de) 1998-02-25
ES2217287T3 (es) 2004-11-01
DK0792275T3 (da) 2004-07-05
CA2205136A1 (en) 1996-05-23
EP0792275B1 (de) 2004-03-03

Similar Documents

Publication Publication Date Title
DE69532642D1 (de) Antivirale prodrugs
DE69326530D1 (de) Mehrrechnersystem
FI950257L (fi) Imukykyisiä tuotteita, joissa on pikkuhousua peittävät komponentit, jotka sulkevat luonnollisella tavalla housun reunat sisäänsä
DE69129479D1 (de) Verteiltes Rechnersystem
FI943528A7 (fi) Absorbenttituotteita
FI933656A7 (fi) 2,4-diaminokinatsoliinijohdannaiset, jotka tehostavat kasvaintenvastai sta aktiivisuutta
DE69128017D1 (de) Verteiltes rechnersystem
FI935517L (fi) Fenoksi- ja fenoksialkyylipiperidiinejä virusvastaisina aineina
DE69305413D1 (de) Pulverisierungsvorrichtung
KR930702893A (ko) 상보시스템을 저해하거나 또는 면역활성을 억제하는 성분물
FR2591483B1 (fr) Compositions pharmaceutiques antivirales et antitumorales.
DE69327153D1 (de) Anti-hiv-medikament
DE69121446D1 (de) Zerstäubungssystem
DE69328050D1 (de) Rücklaufsperre
NO931008D0 (no) Farmasoeytiske forbindelser
DE69311862D1 (de) Kontinuierliche Dispergiervorrichtung
FI950533L (fi) Seco-nukleosidien liponulkeotidit, niiden valmistaminen sekä niiden käyttö virusten vastaisina lääkkeinä
DE59301723D1 (de) Schalter
IT1229295B (it) Differenziale bloccabile
FI942803A0 (fi) Ipsapironi-lääkevalmiste
KR950702247A (ko) 비타민 d류 히드록시라제유전자
ES1022839Y (es) Bragas monouso.
FI925423L (fi) Anordning foer att anordna permanenta magneter till en maenniskans kropp
AU1871592A (en) Novel reference influenza viruses and antiviral drug susceptibility methods
KR970000135U (ko) 아기용 멜빵

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0792275

Country of ref document: EP

REN Ceased due to non-payment of the annual fee